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This editorial refers to ‘Fractional flow reserve and
pressure-bounded coronary flow reserve to predict out-
comes in coronary artery disease’†, by J.-M. Ahn et al., on
page 1980.
The ‘stenosis centric’ approach to the diagnosis of coronary artery
disease (CAD) neglects the broader pathophysiology of angina and
disorders of coronary artery function (Figure 1). Accordingly, we pro-
pose the term ‘stable coronary artery syndrome’ in order to reflect
the distinct and related pathologies of focal and diffuse CAD, as well
as coronary microvascular and vasospastic disorders, that may reduce
myocardial perfusion and provoke ischaemia in individual patients.
Evidence linking parameters of coronary artery function with prog-
nosis has evolved substantially in the last four decades. Coronary flow
reserve (CFR) was first described as the ratio of maximum stress flow
to rest flow for a given arterial distribution with or without a stenosis
or diffuse narrowing.1 CFR determined non-invasively using positron
emission tomography (PET) is associated with the risk of major ad-
verse cardiac events (MACE) in the future, independent of clinical
variables and the number of ischaemic myocardial segments.2,3
Fractional flow reserve (FFR) was subsequently described as a
pressure-derived index to quantify the relative reduction in coronary
artery blood flow due to a coronary stenosis as compared with the
flow in the same artery in the absence of the stenosis.4 Invasively
measured CFR (via thermodilution or Doppler wire methods) is re-
ported to be prognostically important even when FFR is preserved.
van de Hoef et al. demonstrated the potential clinical relevance of dis-
cordant CFR and FFR values, showing that in a pooled group of
patients with stable coronary artery disease patients with a reduced
Doppler-derived CFR (defined as <2.0) but preserved FFR (>_0.75)
were at a higher risk of adverse clinical events at 5-year follow-up,
compared with patients with concordantly preserved CFR and FFR
values [relative risk = 5.0, 95% confidence interval (CI) 2.4–10.2; P <
0.001).5 Invasively measured CFR and FFR are discordant in 40% of
patients, which reflects the distinct compartments of the coronary
circulation. Johnson et al. demonstrated that discordant CFR and FFR
values may be explained by fundamental differences in coronary
pathophysiology at the extremes of focal and diffuse CAD.6 For ex-
ample, severe focal epicardial coronary disease may be reflected by a
reduced FFR (<0.80) and a preserved CFR (>2.0), whereas diffuse
coronary plaque without a focal stenosis may be reflected by a pre-
served FFR (>0.8) and a reduced CFR (<2.0) (Figure 1).
In this issue of the journal, Park et al. report their analysis of the
comparative prognostic utility of FFR and ‘pressure-bounded’ coron-
ary flow reserve (pb-CFR) in a study involving 1837 patients (2088
coronary lesions) enrolled in a multicentre South Korean clinical regis-
try.7 pb-CFR is a novel parameter determined by estimating the upper
and lower physiological limits of CFR values using resting and hyper-
aemic pressure data integrated into a mathematical model of pressure
and flow. Pb-CFR was shown to have reasonable diagnostic accuracy
of 84.4% in a recent validation study based on individual patient
haemodynamic data from the DEFER trial.8 Patients in the current
study were dichotomized into two groups based on a low (<2.0) or
high (>_2.0) CFR. A key strength of this analysis is the comparatively
large samples size reflecting a prospectively enrolled population of in-
vasively managed patients with a broad range of CAD severities.
Further, the pb-CFR values were determined post-hoc; therefore, the
data were not available to treating clinicians and so could not have
influenced their clinical decisions. The clinical endpoints were adjudi-
cated by a central committee blind to the pb-CFR values. The investi-
gators found that the composite primary endpoint of MACE (cardiac
death, myocardial infarction, and repeat revascularization) was pre-
dicted by FFR but not by pb-CFR, which had a neutral prognostic im-
plication when adjusted for clinical variables. In a per-lesion analysis,
during a median follow-up of 1.9 years (interquartile range: 1.0–
3.0 years), the incidence of MACE did not differ between lesions with
pb-CFR <2 vs. pb-CFR >_2 [4.0% vs. 4.0%; adjusted hazard ratio (aHR)
= 0.93, 95% CI 0.59–1.48; P = 0.76). FFR was predictive of future
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events, with MACE occurring in 5.7% of lesions with FFR <_0.80 vs.
2.5% of lesions with FFR >0.80 (aHR = 2.46, 95% CI 1.40–4.31; P =
0.002). Incorporation of FFR improved the prediction of MACE (glo-
bal v2 38.8–48.1; P = 0.002); however, pb-CFR did not confer any add-
itional prognostic utility (48.1–48.2; P > 0.99).
The authors should be congratulated for undertaking this large
prospective cohort study including the application of mathemat-
ical modelling to determine pb-CFR. Nonetheless, the study
design is qualified in certain respects. The median follow-up dur-
ation of 1.9 years is rather intermediate for a natural history study
of coronary atherosclerosis, and the composite primary outcome
event rate was predominantly driven by repeat revascularization.
CFR is not a test of coronary atherosclerosis and, while impair-
ment of vasodilator reserve would expectedly be associated with
atherosclerotic plaque burden and thus CAD progression, the ab-
sence of any association between pb-CFR and MACE in this co-
hort should not be a surprise. In the per-lesion analysis (rather
than a more clinically relevant per-patient analysis) investigating
the ‘hard’ secondary endpoints of cardiac death or myocardial in-
farction, there were only 18 events associated with 2088 lesions
(event rate 0.0086%) and, importantly, pb-CFR <2.0 was an inde-
pendent predictor of these important events (1.5% vs. 0.3%; HR
3.77, 95% CI 1.04–13.7; P = 0.044).
The authors highlight other limitations including the lack of an ab-
solute CFR value and the inclusion of less than a quarter of all the
interrogated lesions (2088 out of 8633), thus potentially introducing
a selection bias. The same limitations of thermodilution and Doppler
wire-derived CFR apply to pb-CFR, namely its susceptibility to vari-
ations in resting haemodynamics. This point is all the more relevant
given that >20% of patients in the current cohort had a recent acute
coronary syndrome. An increase resting coronary flow, such as with
emotional stress, will reduce CFR and so confound any association
between CFR and CAD burden.
Lee et al. recently described the associations between FFR and
microvascular resistance, as revealed by direct invasive measurement
of the index of micro-circulatory resistance (IMR) in 313 patients
(16% with unstable symptoms).9 They found that in patients with pre-
served FFR, the worst clinical outcomes occurred in patients in the
low CFR (<2.0) and high IMR (>_23) group (aHR = 4.914, 95% CI
1.541–15.663; P = 0.007), as compared with groups with other CFR/
IMR combinations. Unlike FFR, the utility of CFR in clinical practice is
limited by the lack of a clearly defined abnormal threshold, and the
general influence of both epicardial and microvascular compartments.
Ascribing a binary cut-off value for abnormal/normal CFR ignores its
continuous stepwise prediction of MACE akin to blood pressure.10
FFR remains the evidence-based physiological test for epicardial
CAD to inform revascularization decisions in clinical practice. Where
appropriate, we advocate direct invasive measurement of micro-
vascular function [with IMR11 or the Doppler-derived hyperaemic
microvascular resistance (HMR)], in addition to CFR, in order to as-
sess comprehensively the contribution of each coronary compart-
ment to a patient’s symptoms. pb-CFR is currently available and can
be generated automatically from invasive pressure data on next-
generation haemodynamic consoles (e.g. Coroventis Research AB).
Of course, its utility is based on the premise that pb-CFR, or more
fundamentally CFR, is a clinically useful parameter to inform revascu-
larization decisions, which remains the subject of much debate. In this
regard, more research is needed.
The study by Park et al. in this issue fuels the debate regarding
whether the clinical utility of coronary revascularization (i.e. the
benefit to patients) can be further refined by incorporating ad-
junctive information using CFR in addition to (or even instead of)
FFR in order to improve clinical outcomes.12 The DEFINE-FLOW
(Distal Evaluation of Functional Performance With Intravascular
Sensors to Assess the Narrowing Effect – Combined Pressure and
Doppler FLOW Velocity Measurements, clinicaltrials.gov
NCT02328820) study is currently examining this question. In
DEFINE-FLOW, percutaneous coronary intervention (PCI) is in-
tended to be performed in patients with an epicardial coronary
stenosis with concordantly reduced FFR (<_0.8) and CFR (<2.0)
values. On the other hand, medical therapy would be considered
for a patient with a diseased coronary artery (FFR <_ 0.80) associ-
ated with a normal CFR >_2.0.
In patients with a known or suspected coronary artery syndrome,
as clinicians we are fortunate now to have diagnostic tools that en-
able a comprehensive assessment of the functional significance of
CAD beyond visual interpretation of the angiogram. The remaining
challenges include clinical acumen (listening to our patients), educa-
tion, technology adoption, and importantly, the gaps in clinical evi-
dence to link treatment decisions informed by the use of such tests
with improvements in patient wellbeing.
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Figure 1 Stable coronary artery syndromes: different combin-
ations of focal, diffuse, and microvascular coronary artery disease
(CAD) contribute to myocardial ischaemia. Extreme forms of focal
or diffuse coronary disease may result in discordant abnormalities
of either fractional flow reserve (FFR) or coronary flow reserve
(CFR), respectively. IMR, index of micro-circulatory resistance.
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